Clinic
Dignity Health
Dignity Health was paid $28.47M by Medicaid between Aug 2018 and Dec 2024, across 114 billing codes. Its largest line is T1015, a visit at a community health center or clinic (one all-in rate) — 82% of everything it billed.
33Billing provider infoDIGNITY HEALTH
RED BLUFF, CA 96080
RED BLUFF, CA 96080
33aNPI1407399678assigned 11/21/2016
33bProvider typeRural Health Clinic/Center
28Total paid$28.47M
24GClaims606,429
24DCodes billed114
24AFirst – last monthAug 2018 – Dec 2024
Compared with peers
Next to other Rural Health Clinic/Center providers in California
Rank by total paid#11 of 215
Median peer was paid$3.62M
This provider vs. median7.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MIRANDA, KIM controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,425 | $1.24M | |
| 2019 | 96,729 | $4.71M | |
| 2020 | 83,099 | $4.05M | |
| 2021 | 92,841 | $4.60M | |
| 2022 | 84,276 | $3.92M | |
| 2023 | 117,197 | $5.79M | |
| 2024incomplete | 109,862 | $4.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 82% | 130,214 | 119,351 | $23.24M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.1% | 116,310 | 64,805 | $1.44M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.9% | 51,659 | 31,044 | $833K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 14,378 | 8,007 | $253K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 11,475 | 6,410 | $231K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 7,343 | 4,353 | $223K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 11,053 | 7,043 | $165K |
| G9920 | Screening performed and negative | <1% | 11,634 | 6,688 | $160K |
| G0467 | Community health center visit, returning patientFederally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | <1% | 7,825 | 7,048 | $153K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,922 | 1,904 | $147K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 4,035 | 3,956 | $141K |
| 92551 | <1% | 23,258 | 13,027 | $116K |
102 more codes
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 4,660 | $112K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,940 | $96K |
| 17110 | <1% | 1,653 | $88K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 10,528 | $87K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 14,934 | $78K |
| 87634 | <1% | 1,307 | $77K | |
| 11102 | <1% | 1,302 | $61K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,466 | $58K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 3,282 | $55K |
| 80053 | Comprehensive metabolic panel | <1% | 4,983 | $43K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 11,913 | $43K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 22,499 | $38K |
| 90686 | <1% | 9,084 | $37K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,033 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,649 | $27K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,561 | $26K |
| 83655 | <1% | 2,147 | $26K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,338 | $25K |
| 80061 | Lipid panel | <1% | 2,080 | $24K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,455 | $23K |
| 99173 | <1% | 20,245 | $22K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,278 | $20K |
| 90670 | <1% | 6,697 | $20K | |
| 17000 | <1% | 735 | $18K | |
| 87400 | <1% | 1,594 | $18K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 290 | $15K |
| 90648 | <1% | 4,704 | $15K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,716 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,384 | $14K |
| 90633 | <1% | 4,336 | $13K | |
| 99188 | <1% | 1,167 | $12K | |
| 90723 | <1% | 3,083 | $9K | |
| 99381 | <1% | 407 | $9K | |
| 90677 | <1% | 1,345 | $9K | |
| 90651 | <1% | 1,651 | $9K | |
| 90698 | <1% | 2,971 | $8K | |
| 90680 | <1% | 2,157 | $6K | |
| 96127 | <1% | 1,489 | $5K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 311 | $5K |
| 85018 | <1% | 2,699 | $5K | |
| 11104 | <1% | 77 | $5K | |
| G9919 | Screening performed and positive and provision of recommendations | <1% | 311 | $5K |
| 81003 | <1% | 4,330 | $5K | |
| 0002A | <1% | 99 | $5K | |
| 90744 | <1% | 1,935 | $5K | |
| 85027 | <1% | 793 | $5K | |
| 99000 | <1% | 1,329 | $4K | |
| 90734 | <1% | 1,067 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 141 | $3K |
| 81025 | <1% | 1,890 | $3K | |
| 0001A | <1% | 73 | $3K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 109 | $3K |
| 87807 | <1% | 229 | $2K | |
| 90710 | <1% | 587 | $2K | |
| 90681 | <1% | 820 | $2K | |
| 11100 | <1% | 80 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 318 | $2K |
| 90656 | <1% | 434 | $2K | |
| 92588 | <1% | 63 | $1K | |
| 17003 | <1% | 222 | $1K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 35 | $1K |
| 99383 | <1% | 42 | $1K | |
| 90696 | <1% | 335 | $989.44 | |
| 69210 | <1% | 77 | $969.95 | |
| 90707 | <1% | 269 | $965.14 | |
| 90715 | <1% | 224 | $944.82 | |
| 90700 | <1% | 261 | $922.62 | |
| 90716 | <1% | 295 | $850.20 | |
| 99384 | <1% | 22 | $733.00 | |
| 99283 | Emergency room visit (moderate) | <1% | 43 | $641.21 |
| 11200 | <1% | 52 | $613.63 | |
| 90480 | <1% | 16 | $560.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 150 | $544.54 |
| 82043 | <1% | 111 | $493.14 | |
| 82570 | <1% | 83 | $345.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,396 | $308.42 |
| 99205 | Prolong outpt/office vis | <1% | 17 | $248.10 |
| 86140 | <1% | 52 | $226.48 | |
| 80076 | <1% | 28 | $211.16 | |
| 85610 | <1% | 121 | $187.73 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 274 | $179.58 |
| 87081 | <1% | 14 | $79.52 | |
| 81001 | <1% | 12 | $32.48 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 14 | $32.25 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 673 | $4.24 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 65 | $1.08 |
| 3077F | 0% | 209 | $0.00 | |
| 3078F | 0% | 6,768 | $0.00 | |
| 3725F | 0% | 601 | $0.00 | |
| 1160F | 0% | 191 | $0.00 | |
| 1159F | 0% | 191 | $0.00 | |
| 90662 | 0% | 13 | $0.00 | |
| G0466 | Community health center visit, new patient | 0% | 12 | $0.00 |
| 3074F | 0% | 6,896 | $0.00 | |
| 3008F | 0% | 5,959 | $0.00 | |
| 1036F | 0% | 5,297 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 44 | $0.00 |
| 3075F | 0% | 557 | $0.00 | |
| 3079F | 0% | 799 | $0.00 | |
| 3080F | 0% | 86 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 27 | $0.00 |
| 3044F | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMIRANDA, KIM (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Alameda Health System | Oakland, CA | $64.53M |
| Alameda Health System | Oakland, CA | $57.80M |
| Dignity Health | Cottonwood, CA | $8.28M |
| Dignity Health | Red Bluff, CA | $4.59M |
| Dignity Health | Mount Shasta, CA | $2.82M |
| Dignity Health | Redding, CA | $1.58M |
| Dignity Health | Redding, CA | $1.34M |
| Dignity Health | Mount Shasta, CA | $1.28M |
| Dignity Health | Weed, CA | $981K |
| Alameda Health System | Hayward, CA | $392K |
| Dignity Health | Redding, CA | $273K |
| Dignity Health | Red Bluff, CA | $134K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.